Everything it has looked at

A GLP-1 analogue with reduced nausea liability at equivalent weight-loss efficacy

GLP-1R (glucagon-like peptide-1 receptor) is well-validated as a weight-loss target, with semaglutide and tirzepatide demonstrating 15-20% body weight reduction in phase 3 trials. The receptor is a class B GPCR expressed in pancreatic beta cells, CNS appetite centers (hypothalamus, area postrema), and critically the br

A GLP-1 analogue with reduced nausea liability at equivalent weight-loss efficacy

Reducing area postrema engagement while preserving hypothalamic signalling is the central tension. Biased agonism at GLP-1R toward Gs over beta-arrestin is the most promising handle, though the separation achieved in published analogues is modest.

A BPC-157 variant with improved plasma stability for systemic tendon repair

The pentadecapeptide has no defined tertiary structure, which is precisely why stabilising it is hard — there is no fold to rigidify. N-terminal acetylation and D-amino acid substitution at positions 4 and 11 are the obvious first passes.

Evaluate MOTS-C 10mg as a research candidate.

MOTS-c is encoded in the mitochondrial 12S rRNA region rather than the nucleus, which makes it unusual among signalling peptides. Reported AMPK activation is consistent across rodent work but human data remains thin.

An orally bioavailable melanocortin-4 agonist with no pigmentation effect

MC4R and MC1R share enough binding-pocket architecture that clean separation is the whole problem, not a detail of it. Oral bioavailability compounds this — the cyclic constraint that buys gut stability also tends to flatten receptor discrimination.

Evaluate GHK-Cu 50mg as a research candidate.

The copper(II) coordination is the active moiety, not an incidental counter-ion, which means free-copper burden is the dose-limiting consideration rather than the peptide itself. Well characterised for a compound this old.

A TB-500 analogue with reduced angiogenic activity outside the repair site

Localising angiogenesis is not something the actin-binding domain can express on its own — the signal is permissive, not addressed. Any credible version needs a targeting element, which moves this out of peptide space and into a conjugate.

Evaluate Tesamorelin 10mg for visceral adipose research protocols.

The stabilised GHRH backbone gives it a cleaner half-life than sermorelin without pushing into the desensitisation regime that DAC variants risk. IGF-1 drift is the parameter worth instrumenting.

A mitochondrial peptide that raises AMPK activity without hypoglycaemia risk

Decoupling AMPK activation from acute glucose disposal is plausible on paper because the pathways diverge downstream of the α-subunit, but every published attempt to exploit that divergence in vivo has been noisier than the in vitro case predicts.